Chimeric Antigen Receptor (CAR) that Targets Chemokine Receptor CCR4 and its Use in Treating Cancer


The chemokine receptor CCR4 is a seven-transmembrane G protein-coupled cell surface receptor molecule with selective expression on cells of the hematopoietic system. In adult T cell leukemia (ATL), the cell-surface expression of CCR4 on leukemic cells has been found to be nearly universal. Therefore, a CCR4-directed CAR-cell may provide an effective therapeutic against ATL.

Researchers at the National Cancer Institute, Lymphoid Malignancies Branch developed a lentivirus-derived chimeric antigen receptor (CAR) against the CCR4 molecule. The CAR can be directed to either genetically modified autologous or to allogeneic T- or NK-cells to develop the ATL therapy. This technology also includes a method of identifying lymphoid or solid tumors that produce CCR4 mRNA and then utilizing CD3+ T cells and/or natural killer (NK) cells to generate genetically modified T cells and/or NK cells (autologous or allogeneic) that express the CCR4 directed chimeric antigen receptor. The identified malignancy can then be treated with the infusion of genetically modified T- or NK cells.



Potential Commercial Applications: Competitive Advantages:
  • Identification and treatment of CCR4 mRNA producing lymphoid or solid neoplasms
 
  • CCR4 is a new target for cell-base immunotherapy
  • Allogenic NK cells would enable wider use of cell-based therapies


Development Stage:
Discovery (Lead Identification)

Inventors:

Liyanage Perera (NCI)  ➽ more inventions...

Thomas Waldmann (NCI)  ➽ more inventions...

Kevin Conlon (NCI)  ➽ more inventions...


Intellectual Property:
Application No. PCT/US2017/052437

Publications:
Perera, L., et al. PMID 28543380

Collaboration Opportunity:

Licensing and research collaboration


Licensing Contact:
John Hewes, Ph.D.
Email: John.Hewes@nih.gov
Phone: 240-276-5515

OTT Reference No: E-258-2016
Updated: Apr 23, 2019